APL-1401

Jiangsu Yahong Meditech Co., Ltd aka Asieris · Phase 1 active Small molecule

At a glance

Generic name	APL-1401
Also known as	Nepicastat, SYN117
Sponsor	Jiangsu Yahong Meditech Co., Ltd aka Asieris
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1b Study to Evaluate APL-1401 in Patients With Moderately to Severely Active Ulcerative Colitis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

APL-1401 CI brief — competitive landscape report
APL-1401 updates RSS · CI watch RSS
Jiangsu Yahong Meditech Co., Ltd aka Asieris portfolio CI